检索结果-南通市图书馆

偶发性局灶性实性肝脏病变:对比增强超声及MRI诊断作用

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

国际医学放射学杂志 2010年第5期 499-499页

作者： M.Soussan C.Aubé S.Bahrami j.boursier D.C.Valla V.Vilgrain 李华兵 Department of Radiology Assistance Publique des H?pi-taux de ParisAPHPH?pital Beaujon

FibroMeters:诊断肝纤维化的血液学检测指标组合(英文)

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

传染病信息 2013年第3期26卷 134-140页

作者： Paul Calès jérme boursier Frédéric Oberti Isabelle Hubert Yves Gallois Marie Christine Rousselet Valérie Moal Laurent Macchi Alain Chevailler julien Chaigneau Gilles Hunault HIFIH Laboratory LUNAM University Hepato-gastroenterology department University Hospital Biochemistry Laboratory Hepato-gastroenterology department University Hospital Pathology department University Hospital Hematology Laboratory University Hospital Immunology Laboratory University Hospital

FibroMeters是具有多项特异性的诊断肝纤维化的血液学检测指标组合,其3个主要诊断目标为显著肝纤维化、肝硬化以及肝纤维化的定量,并由专业系统针对不同病因进行调整从而保证获得准确的结果。因此,主要存在 6 种不同的 FibroMeters:即... 详细信息

FibroMeters是具有多项特异性的诊断肝纤维化的血液学检测指标组合,其3个主要诊断目标为显著肝纤维化、肝硬化以及肝纤维化的定量,并由专业系统针对不同病因进行调整从而保证获得准确的结果。因此,主要存在 6 种不同的 FibroMeters:即针对肝纤维化的3种主要病因慢性病毒性肝炎、酒精性肝病和非酒精性脂肪性肝病的肝纤维化分期和肝纤维化定量。以肝组织病理学方法诊断肝纤维化程度进行对照,FibroMeters 表现出非常高的诊断准确率,是惟一能100%正确区分丙型肝炎患者不伴有肝纤维化或伴有肝硬化的检测方法。在适用性方面,FibroMeters 对于显著肝纤维化的 90%预测值高于其他血清学检测方法。使用包括 7 类内容在内的详细的肝纤维化分期方法,87%的丙型肝炎患者可以获得准确的肝纤维化分期。在实际工作条件下,FibroMeters 重复性高于肝组织病理结果,也高于超声弹性检测。因诊断性能表现非常稳定,FibroMeters 在不同的中心都是稳健的检测方法。目前可选择的检测有:针对肝硬化诊断的 CirrhoMeter,在一项丙型肝炎肝硬化患者的队列中其诊断准确率为 93%(受试者工作特征曲线下面积:0.92),阳性预测值为 100%;针对肝纤维化定量检测的QuantiMeter,是惟一能通过无创方法直接量化肝纤维化程度的手段,对于随访肝硬化及其临床相关事件可能特别有用。除HCV 感染外,FibroMeters对HBV或HIV同时感染患者诊断准确率高,尤其是对酒精性肝病或非酒精性脂肪肝患者,FibroMeters有较高的诊断准确率(对于显著纤维化,受试者工作特征曲线下面积分别为0.96和0.94)。

关键词：肝纤维化活组织检查血清学弹性显像技术

维普期刊数据库

人类小肠IgA反应在集结的肠黏膜相关淋巴组织中产生,并非在固有膜中产生

在线全文

学校读者我要写书评

暂无评论

世界核心医学期刊文摘（胃肠病学分册） 2005年第10期1卷 28-28页

作者： boursier L. Gordon j.N. Thiagamoorthy S. j. Spencer 王铮 Department of Immunobiology GKT Medical School New Guy's House St. Thomas Street London SE1 9RT United Kingdom Dr.

Background &Aims: The intestinal lamina propria has traditionally been viewed as the effector site of mucosal immune responses. However, this view has been challenged with the identification, in the murine lamina propria, of an in situ class switch DNA recombination pathway to IgA. In this study, we tested the hypothesis that in situ class switching occurs in the human lamina propria. Methods: Immunohistochemistry was used to analyze tissue microenvironments and RT-PCR to look for molecular evidence of Ig class switching and to track clonally related cells of B lineage. Results: We found no evidence of proliferation of either lamina propria CD20+or CD19+cells or evidence of activation-induced cytidine deaminase mRNA expression outside the organized gut-associated lymphoid tissue, although Iα-Cαimmunoglobulin germ-line gene transcript expression could be identified in the lamina propria. We identified clonally related cells, including IgA and IgM isotype-switched variants, in multiple samples known to be free of activation-induced cytidine deaminase, organized lymphoid tissue, or cellular proliferation. For 4 groups of cells, the patterns of somatic mutations on the rearranged IgVH5 gene segment were more similar between cells from distant sites than from their immediate neighbors, implying dissemination of cells from a common set of precursors. Conclusions: Our data are inconsistent with a model in which precursors of human IgA-secreting plasma cells are induced or expanded in the lamina propria. The human lamina propria is therefore likely to solely be an effector site of intestinal secretory IgA responses that originate from the organized gut-associated lymphoid tissues.

关键词：固有膜 IgA 类别转换固有层组织微环境黏膜免疫免疫组化技术免疫球蛋白分子学胞嘧啶核苷

维普期刊数据库

An international Delphi consensus statement on metabolic dysfunction-associated fatty liver disease and risk of chronic kidney disease

在线全文

学校读者我要写书评

暂无评论

Hepatobiliary Surgery and Nutrition 2023年第3期12卷 386-403,I0014-I0016页

作者： Dan-Qin Sun Giovanni Targher Christopher D.Byrne David C.Wheeler Vincent Wai-Sun Wong jian-Gao Fan Herbert Tilg Wei-jie Yuan Christoph Wanner Xin Gao Michelle T.Long Mehmet Kanbay Mindie H.Nguyen Sankar D.Navaneethan Yusuf Yilmaz Yuli Huang Rino A.Gani Pierluigi Marzuillo jérôme boursier Huijie Zhang Chan-Young jung jin Chai Luca Valenti George Papatheodoridis Giovanni Musso Yu-jun Wong Mohamed El-Kassas Nahum Méndez-Sánchez Silvia Sookoian Michael Pavlides Ajay Duseja Adriaan G.Holleboom junping Shi Wah-Kheong Chan Yasser Fouad junwei Yang Sombat Treeprasertsuk Helena Cortez-Pinto Masahide Hamaguchi Manuel Romero-Gomez Mamun Al Mahtab Ponsiano Ocama Atsushi Nakajima Chunsun Dai Mohammed Eslam Lai Wei jacob George Ming-Hua Zheng Department of Nephrology Jiangnan University Medical CenterWuxiChina Affiliated Wuxi Clinical College of Nantong University WuxiChina Section of Endocrinology Diabetes and MetabolismDepartment of MedicineAzienda Ospedaliera Universitaria Integrata VeronaVeronaItaly Southampton National Institute for Health and Care Research Biomedical Research Centre University Hospital Southamptonand Southampton General HospitalUniversity of SouthamptonSouthamptonUK Department of Renal Medicine University College LondonLondonUK Department of Medicine and Therapeutics Chinese University of Hong KongHong KongChina Center for Fatty Liver Department of GastroenterologyXin Hua Hospital Affiliated to Shanghai Jiao Tong University School of MedicineShanghaiChina Department of Internal Medicine I GastroenterologyEndocrinology&MetabolismMedical University InnsbruckInnsbruckAustria Department of Nephrology Shanghai General HospitalShanghai Jiao Tong University School of MedicineShanghaiChina Division of Nephrology Department of MedicineWürzburg University ClinicWürzburgGermany Department of Endocrinology and Metabolism Zhongshan HospitalFudan UniversityShanghaiChina Section of Gastroenterology Boston Medical CenterBoston University School of MedicineBostonMAUSA Division of Nephrology Department of Medicine(M.K.)Koc University School of MedicineIstanbulTurkey Division of Gastroenterology and Hepatology Department of MedicineStanford University Medical CenterPalo AltoCAUSA Department of Epidemiology and Population Health Stanford University Medical CenterPalo AltoCAUSA Section of Nephrology and Institute of Clinical and Translational Research Baylor College of Medicineand Michael E.DeBakey VA Medical CenterHoustonTXUSA Department of Gastroenterology School of MedicineMarmara UniversityIstanbulTurkey Department of Gastroenterology School of MedicineRecep Tayyip Erdoğan UniversityRizeTurkey Department of Cardiology Shunde HospitalSouthern Medical UniversityFoshanChina Division of Hepat

Background:With the rising global prevalence of fatty liver disease related to metabolic dysfunction,the association of this common liver condition with chronic kidney disease(CKD)has become increasingly *** 2020,the more inclusive term metabolic dysfunction-associated fatty liver disease(MAFLD)was proposed to replace the term non-alcoholic fatty liver disease(NAFLD).The observed association between MAFLD and CKD and our understanding that CKD can be a consequence of underlying metabolic dysfunction support the notion that individuals with MAFLD are at higher risk of having and developing CKD compared with those without ***,to date,there is no appropriate guidance on CKD in individuals with ***,there has been little attention paid to the link between MAFLD and CKD in the Nephrology *** and Results:Using a Delphi-based approach,a multidisciplinary panel of 50 international experts from 26 countries reached a consensus on some of the open research questions regarding the link between MAFLD and ***:This Delphi-based consensus statement provided guidance on the epidemiology,mechanisms,management and treatment of MAFLD and CKD,as well as the relationship between the severity of MAFLD and risk of CKD,which establish a framework for the early prevention and management of these two common and interconnected diseases.

关键词： Metabolic dysfunction-associated fatty liver disease(MAFLD) non-alcoholic fatty liver disease(NAFLD) chronic kidney disease(CKD) consensus